Skip to main content
Premium Trial:

Request an Annual Quote

Beijing Genomics Institute to Offer Sequencing Services on Sanger, Solexa, SOLiD Instruments

NEW YORK (GenomeWeb News) – The Beijing Genomics Institute said yesterday that it plans to use its fleet of 120 Sanger and next-generation sequencing instruments to offer sequencing services to the global market.
In a statement, BGI said that it currently has more than 120 sequencers, which includes Applied Biosystems 3730xl sequencers, Amersham MegaBace sequencers, seven Illumina Genome Analyzers, and two ABI SOLiDs. The institute said these instruments enable a sequencing throughput of 250 million base pairs per day using Sanger and 4 billion base pairs per day using the next-generation instruments.
BGI said that it plans to provide these services at “dramatically reduced cost and improved speed,” but did not provide further details.
The institute said it considers its bioinformatics capabilities to be an advantage in the sequencing services market. BGI said it has more than 100 bioinformatics specialists, 2,000 CPUs, and more than 500 terabytes of storage.
In addition to sequencing, BGI said it will offer bioinformatics services including sequence data processing, sequence assembly, gene annotation, expression level research, EST and microarray analysis, SNP discovery, genotype and haplotype analysis, primer design, software development, system integration, structure modeling, and database and website construction.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.